Beta Bionics (BBNX) Registration Filing summary

Company overview and business model

• Commercial-stage medical device company focused on improving diabetes management for insulin-requiring patients using adaptive closed-loop algorithms.

• Flagship product, the iLet Bionic Pancreas, is FDA-cleared for type 1 diabetes (T1D) in patients six years and older, automating all insulin dosing without carb counting.

• iLet integrates with leading CGMs (Dexcom G6/G7, Abbott FreeStyle Libre 3 Plus) and requires only body weight for initialization.

• Business model includes recurring revenue from single-use products (cartridges, infusion sets) and a multi-channel reimbursement strategy (DME and pharmacy benefit plans).

• Pipeline includes a patch pump and a bihormonal iLet (insulin and glucagon), with plans to expand into insulin-dependent type 2 diabetes (T2D).

Financial performance and metrics

• Revenue grew from $3.1M in Q3 2023 to $16.7M in Q3 2024; nine-month 2024 revenue was $44.7M, up from $3.6M in the prior year period.

• Net losses were $25.3M for the nine months ended September 30, 2023, and $36.6M for the same period in 2024.

• Gross margin for 2023 was 52.6%; for the nine months ended September 30, 2024, gross margin was 54%.

• Accumulated deficit was $278.6M as of September 30, 2024.

• Majority of new patient starts (67% as of September 30, 2024) came from patients previously using multiple daily injections (MDI).

Use of proceeds and capital allocation

• Net proceeds from the IPO will fund: (i) development and regulatory submissions for the bihormonal iLet and glucagon product, (ii) patch pump development and manufacturing, and (iii) expansion of sales/manufacturing infrastructure, working capital, and general corporate purposes.

• No proceeds will be received from shares sold by selling stockholders.